Switch study for reversibility of dolutegravir-based CNS neurotoxicity in virologically suppressed adults with HIV

Phase 4, randomised, open-label trial of abacavir, lamivudine, dolutegravir, tenofovir alafenamide, emtricitabine and 2 more in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Fundación SEIMC-GeSIDA. Primary endpoints: Change in proportion of patients self-reporting insomnia at week 4, Change in neuropsychiatric symptoms at week 4 and 3 more. Started Aug 2018; status: active.